We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Aviva Plc | LSE:AV. | London | Ordinary Share | GB00BPQY8M80 | ORD 32 17/19P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-2.00 | -0.42% | 468.70 | 468.60 | 468.80 | 469.80 | 465.70 | 465.70 | 628,616 | 08:57:17 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Insurance Carriers, Nec | 41.43B | 1.09B | 0.3962 | 11.88 | 12.89B |
Date | Subject | Author | Discuss |
---|---|---|---|
09/3/2017 08:24 | Just in case anyone can't be bothered wading through 2 million pages to the end of part 4 of the announcement for the unimportant dividend details:- 2017 financial calendar Ordinary 2016 final dividend ex-dividend date* 6 April 2017 2016 final dividend record date (Ordinary and ADR) 7 April 2017 Last day for Dividend Reinvestment Plan and currency election for 2016 final dividend 25 April 2017 Annual General Meeting 11am on 10 May 2017 2016 final dividend payment date* 17 May 2017 | cwa1 | |
09/3/2017 08:13 | Pah! Share buybacks are a waste of shareholders' money. Give me the cash. Great numbers and a great outlook though. Another good year ahead. £6 by Christmas - no ramp intended. | lord gnome | |
09/3/2017 08:06 | Wynmack you beat me to it 😀 | dr biotech | |
09/3/2017 08:05 | Wilson on CNBC says rather will move towards a payout ratio of 50%. Capital return next year more likely to be a share buyback. | dr biotech | |
09/3/2017 08:05 | Mark Wilson on cnbc...cap return."maybe in the form of a buyback" | wynmck | |
09/3/2017 07:54 | CWA1 Thanks for that info, plenty to wade through on these results. Did you clock the date and amount of the normal divi as well. Thanks again. | billy5 | |
09/3/2017 07:51 | At the VERY top!! We are now actively planning a capital return to our shareholders and debt reduction in 2017 and will invest further to grow our businesses. | cwa1 | |
09/3/2017 07:47 | Oggyrocks, Special divi? Where is that mentioned in results? | utyinv | |
09/3/2017 07:26 | Look excellent. Special divided on way too. | oggyrocks | |
09/3/2017 07:07 | Profit · Operating profit2,3 up 12% to £3,010 million (2015: £2,688 million4) · Operating EPS2,3 up 3% to 51.1p (2015: 49.7p4) · Operating profit and operating EPS exclude the impact of the change in the Ogden discount rate in UK general insurance, which has been classified as an exceptional item · IFRS profit after tax down 22% to £859 million (2015: £1,097 million4) including the £380 million after-tax charge due to the reduction in the Ogden discount rate 1B1BCapital · Solvency II capital surplus5 £11.3 billion (2015: £9.7 billion) · Solvency II coverage ratio5,6 of 189% (2015: 180%) · Solvency II operating capital generation £3.5 billion · Net asset value up 6% to 414p per share (2015: 390p4) · Holding company liquidity7 £1.8 billion (2015: £1.3 billion) 2B2B15BCash · 2016 total dividend up 12% to 23.3p (2015: 20.8p) · Dividend pay-out ratio 46% (2015: 42%4), progress towards 50% target · Cash remittances up 20% to £1,805 million (2015: £1,507 million) 3B3B16BGrowth · General insurance net written premiums3 up 15% to £8,211 million (2015: £7,171 million) · Life insurance value of new business up 13% to £1,352 million (2015: £1,192 million) · Fund management operating profit up 30% to £138 million (2015: £106 million) · AIMS AUM trebled to £9 billion (2015: £3 billion) · Total group assets under management up to £450 billion 4B4B17BCombined ratio · General insurance combined operating ratio 95.2% (2015: 94.6%) excluding the Ogden discount rate impact. Including the Ogden impact, the combined operating ratio was 101.1%. | skinny | |
08/3/2017 08:15 | Why would anyone red tick a bullish post??? ;)) | alphorn | |
07/3/2017 21:10 | Results under Wilson have exceeded forecasts so far and the so has gone up on results day. I'm not so sure this time, but AV doesn't keep me awake guessing like it used to either | dr biotech | |
07/3/2017 17:26 | Closed out some naked calls today as expecting results to be okish. Small loss, but am now net long. | alphorn | |
07/3/2017 12:45 | Of course! | bracke | |
07/3/2017 12:26 | A position I suspect you are well versed in. | uppompeii | |
07/3/2017 11:18 | Hmmmmm....... a considered trade based on a branch of fundamentals sometimes referred to as the 'revenge' analysis. This has the added advantage that if it is successful the satisfaction index is greatly increased beyond mere cash, not to mention that the investor considers it a move to the moral high ground. | bracke | |
07/3/2017 11:08 | Added some in anticipation of karma for Moss screwing me over round about this time 5 or 6 years ago... | uppompeii | |
01/3/2017 15:47 | One hidden bonus, I bought some av.b shares in December and theyve quietly added around 5%. | uppompeii | |
01/3/2017 12:00 | Well there's half your fence! | skinny | |
01/3/2017 11:59 | Good day uppompeii Mr Trumps speech not assisted the share price much. It's still 'piddling' around with 500. Doesn't inspire apart from the odd 10p. | bracke | |
28/2/2017 18:55 | Some longer term sipp but a quick 10p to replace some fencing taken down last week...sounds fair I believe | uppompeii | |
28/2/2017 17:20 | Good day uppompeii No ire and not necessarily a bad move. It depends on your target and what you are looking to achieve. As may be expected the share price is meeting resistance at 500. It's broken up a couple of times but unable to stay there. It has been forming a base at 493. Following the intraday high of 512 it dropped to 493. It did try again but could not get to 512 and again dropped to 493. Depends which gives first 500 or 493. Perhaps Mr Trump's speech will resolve the situation. | bracke | |
28/2/2017 15:16 | May take a nibble here again before results, hoping not to raise bracke's ire but I'm sure he will say it's a bad move.... | uppompeii | |
22/2/2017 13:56 | Apparently the Spanish assets may soon be sold, according to Bloomberg. | dr biotech | |
19/2/2017 16:37 | Well aside the 93% that are held by banks and nominee companies! | uppompeii |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions